A recent study revealed that inhibiting FASN can protect MHC-I from lysosomal degradation and increase MHC-I levels on the surface of HCC cells, thus enhancing CD8+ T cell cytotoxicity[93]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.